Publications by authors named "Gregory C Fanning"

Claim this Profile
A
Author Correction: Therapeutic strategies for hepatitis B virus infection: towards a cure.
Gregory C Fanning, Fabien Zoulim, Jinlin Hou, Antonio Bertoletti

Nat Rev Drug Discov· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic strategies for hepatitis B virus infection: towards a cure.
Gregory C Fanning, Fabien Zoulim, Jinlin Hou, Antonio Bertoletti

Nat Rev Drug Discov· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage.
Benoit Devogelaere, Jan Martin Berke, Leen Vijgen, Pascale Dehertogh, Els Fransen, Gregory C Fanning

Antimicrob Agents Chemother· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase.
Jan Martin Berke, Leen Vijgen, Sophie Lachau-Durand, Megan H Powdrill, Svea Rawe, Gregory C Fanning

Antimicrob Agents Chemother· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of stem length and core placement on shRNA activity.
Glen J McIntyre, Yi-Hsin Yu, Mehnaaz Lomas, Gregory C Fanning

BMC Mol Biol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of multiple shRNA expression methods for combinatorial RNAi.
Glen J McIntyre, Allison J Arndt, Kirsten M Gillespie, Wendy M Mak, Gregory C Fanning

Genet Vaccines Ther· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
Oliver Lenz, Thierry Verbinnen, Tse-I Lin, Leen Vijgen, Maxwell D Cummings, Gregory C Fanning

Antimicrob Agents Chemother· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
Henk W Reesink, Gregory C Fanning, Khalid Abou Farha, Christine Weegink, André Van Vliet

Gastroenterology· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus.
Origène Nyanguile, Benoit Devogelaere, Leen Vijgen, Walter Van den Broeck, Frederik Pauwels, Gregory C Fanning

J Virol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and cloning strategies for constructing shRNA expression vectors.
Glen J McIntyre, Gregory C Fanning

BMC Biotechnol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients.
Janet L Macpherson, Maureen P Boyd, Allison J Arndt, Alison V Todd, Gregory C Fanning

J Gene Med· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients.
Rafael G Amado, Ronald T Mitsuyasu, Joseph D Rosenblatt, Frances K Ngok, Andreas Bakker, Gregory C Fanning

Hum Gene Ther· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis